Edmond de Rothschild Equity Strategies IV acquires a majority stake in Oncodesign Services
Oncodesign Services, a leading Contract Research Organization (CRO) specializing in drug discovery and preclinical services in oncology and immuno-inflammation, and Elyan Partners have completed the acquisition of a majority stake in Oncodesign Services by Edmond de Rothschild Equity Strategies IV, from its main shareholders, including Philippe Genne, founder of Oncodesign Services.
